PUNE, India, April 16, 2018 /PRNewswire/ --
According to a new market research report "Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022", published by MarketsandMarkets™, the global market is expected to reach USD 19.35 Billion by 2022 from USD 14.73 Billion in 2017, at a CAGR of 5.6%. The increasing global prevalence of infectious diseases, the shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics are some the factors driving the growth of this market.
Browse 85 market data Tables and 35 Figures spread through 170 Pages and in-depth TOC on "Infectious Disease Diagnostics Market"
Early buyers will receive 10% customization on this report
Based on technology, the immunodiagnostics segment accounted for the largest share of the market in 2017
On the basis of technology, the market is broadly segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and others. The immunodiagnostics segment accounted for the largest share of the global Infectious Disease Diagnostics Market in 2017. This dominant share is attributed to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, and increasing awareness about health and fitness.
Based on disease type, the hepatitis segment accounted for the largest share of the market in 2017
On the basis disease type, the market is broadly segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza and others. The hepatitis diagnostics segment accounted for the largest share of the global Infectious Disease Diagnostics Market in 2017 and HAIs diagnostics segment is expected to witness the highest CAGR during the forecast period. The growth of HAIs diagnostics is attributed to factors such as the rising burden of MRSA infections; increasing number of new products launched in the market; and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assays, Xpert MRSA NxG, and ARIES C. difficile assays that are based on the PCR technology.
Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=116764589
Based on end user, the hospital/clinical laboratories segment accounted for the largest share of the market in 2017
On the basis end user, the market is broadly segmented into hospitals/clinical laboratories, reference laboratories, physician offices, academic institutes, and other end users. The hospitals/clinical laboratories segment is projected to register the highest CAGR during the forecast period. The growth of this segment can primarily be attributed to the large number of diagnostic tests carried out in hospitals.
North America dominated the market in 2017
In 2017, North America accounted for the largest share of the global Infectious Disease Diagnostics Market. This largest share is attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
The key players in the global Infectious Disease Diagnostics Market are Abbott (US), Becton, Dickinson and Company (BD) (US), bioMérieux (France), Bio-Rad (US), and Roche (Switzerland).
Know more about the Infectious Disease Diagnostics Market:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
630 Dundee Road
Northbrook, IL 60062
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets